Dr. Nicholas Tiee is a patent agent in the Century City office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm's patents and innovations practice and focuses on patent prosecution and due diligence for clients in biotechnology and diagnostics. Prior to joining the firm, Nicholas performed his doctoral research on protein structure and dynamics on proteins relating to immuno-inflammatory diseases. In addition, he studied kinase kinetics as a model for potential protein evolution systems. Nicholas also has conducted research characterizing single cells in microfluidic devices as well as antibody selection and protein display technologies.
Dr. Nicholas Tiee is a patent agent in the Century City office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm's patents and innovations practice and focuses on patent prosecution and due diligence for clients in biotechnology and diagnostics. Prior to joining the firm, Nicholas performed his doctoral research on protein structure and dynamics on proteins relating to immuno-inflammatory diseases. In addition, he studied kinase kinetics as a model for potential protein evolution systems. Nicholas also has conducted research characterizing single cells in microfluidic devices as well as antibody selection and protein display technologies.
- Ph.D., Chemistry and Biochemistry, University of California, San Diego
- B.S., Cell Biology and Biochemistry, Rice University
- U.S. Patent and Trademark Office
- Ph.D., Chemistry and Biochemistry, University of California, San Diego
- B.S., Cell Biology and Biochemistry, Rice University
- U.S. Patent and Trademark Office
Cytovale’s IntelliSep test is the first and only U.S. Food and Drug Administration (FDA)-cleared cellular host diagnostic indicated for use in hospital emergency departments, where over 80 percent of sepsis cases present. The test, which takes only approximately eight minutes, provides clinicians with a first-ever look into the biology that causes sepsis, enabling care teams to quickly and confidently identify the proper diagnosis and deliver appropriate, patient-centered care. Cytovale will use the proceeds from the financing to build upon its early clinical success and accelerate commercial expansion of IntelliSep to more hospital emergency departments and health systems nationwide.
The Wilson Sonsini team that advised Cytovale on IP matters related to the financing includes Matt Bresnahan, Maysam Pessian, Nicholas Tiee, and Ben Hoar.
For more information, please see Cytovale’s news release.
- Privacy Policy
- Terms of Use
- Accessibility